Tags

Type your tag names separated by a space and hit enter

Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study.
Cephalalgia 1999; 19(7):668-75C

Abstract

Polypharmacy (the prescription of more than one therapy for a single patient) and subcutaneous (s.c.) sumatriptan tolerability were prospectively studied in 12,339 migraineurs, each followed for up to 1 year. Inclusion/exclusion criteria were minimal and mirrored United States Imitrex labeling. Drug usage and compliance monitoring were automatically interfaced with prescription refill. Concomitant drugs were used by 79% of patients, with analgesics, antidepressants, and sedatives used most commonly. No adverse interactions between sumatriptan and neurological drugs were found, possibly reflecting relative inability of the former to cross the blood-brain barrier. No difference in cardiovascular adverse events was associated with oral contraceptive use, which was more common than expected. No other drug class influenced adverse event probability, although sample sizes for these comparisons was sometimes <400 patients. This study confirms the prevalence of polypharmacy in migraine, identifies the drugs used, and concludes that, on a population basis, the tolerability of s.c. sumatriptan, when used according to labeled instructions, is unaffected by these concomitant drugs.

Authors+Show Affiliations

Department of Clinical Biostatistics, GlaxoWellcome Inc., Research Triangle Park, NC, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

10524661

Citation

Putnam, G P., et al. "Migraine Polypharmacy and the Tolerability of Sumatriptan: a Large-scale, Prospective Study." Cephalalgia : an International Journal of Headache, vol. 19, no. 7, 1999, pp. 668-75.
Putnam GP, O'Quinn S, Bolden-Watson CP, et al. Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. Cephalalgia. 1999;19(7):668-75.
Putnam, G. P., O'Quinn, S., Bolden-Watson, C. P., Davis, R. L., Gutterman, D. L., & Fox, A. W. (1999). Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. Cephalalgia : an International Journal of Headache, 19(7), pp. 668-75.
Putnam GP, et al. Migraine Polypharmacy and the Tolerability of Sumatriptan: a Large-scale, Prospective Study. Cephalalgia. 1999;19(7):668-75. PubMed PMID: 10524661.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. AU - Putnam,G P, AU - O'Quinn,S, AU - Bolden-Watson,C P, AU - Davis,R L, AU - Gutterman,D L, AU - Fox,A W, PY - 1999/10/19/pubmed PY - 1999/10/19/medline PY - 1999/10/19/entrez SP - 668 EP - 75 JF - Cephalalgia : an international journal of headache JO - Cephalalgia VL - 19 IS - 7 N2 - Polypharmacy (the prescription of more than one therapy for a single patient) and subcutaneous (s.c.) sumatriptan tolerability were prospectively studied in 12,339 migraineurs, each followed for up to 1 year. Inclusion/exclusion criteria were minimal and mirrored United States Imitrex labeling. Drug usage and compliance monitoring were automatically interfaced with prescription refill. Concomitant drugs were used by 79% of patients, with analgesics, antidepressants, and sedatives used most commonly. No adverse interactions between sumatriptan and neurological drugs were found, possibly reflecting relative inability of the former to cross the blood-brain barrier. No difference in cardiovascular adverse events was associated with oral contraceptive use, which was more common than expected. No other drug class influenced adverse event probability, although sample sizes for these comparisons was sometimes <400 patients. This study confirms the prevalence of polypharmacy in migraine, identifies the drugs used, and concludes that, on a population basis, the tolerability of s.c. sumatriptan, when used according to labeled instructions, is unaffected by these concomitant drugs. SN - 0333-1024 UR - https://www.unboundmedicine.com/medline/citation/10524661/Migraine_polypharmacy_and_the_tolerability_of_sumatriptan:_a_large_scale_prospective_study_ L2 - http://journals.sagepub.com/doi/full/10.1046/j.1468-2982.1999.019007668.x?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -